SEGMENTED INFORMATION

6 Months Ended

Jun. 30, 2023

SEGMENTED INFORMATION

SEGMENTED INFORMATION

NOTE 11 - SEGMENTED INFORMATION

At June 30, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

	BioNexus Gene Lab Corp., a Wyoming company
100% owned		100% owned
Bionexus Gene Lab Sdn. Bhd., a Malaysian company		Chemrex Corporation Sdn. Bhd., a Malaysian company

At June 30, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

For the six months ended June 30, 2023, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

	BioNexus Malaysia			Chemrex			BGLC			Total
	Six months ended June 30, 2023
REVENUE	$	11,932		$	4,932,121		$	-		$	4,944,053
COST OF REVENUE		(7,548	)		(4,227,894	)		-			(4,235,442	)
GROSS PROFIT		4,384			704,227			-			708,611
OTHER INCOME		2,165			310,343			-			312,508
OPERATING EXPENSES
General and administrative		(98,720	)		(1,025,896	)		(219,333	)		(1,343,949	)
LOSS FROM OPERATIONS		(92,171	)		(11,326	)		(219,333	)		(322,830	)
FINANCE COSTS		(1,275	)		(4,212	)		-			(5,487	)
LOSS BEFORE TAX		(93,446	)		(15,538	)		(219,333	)		(328,317	)
Tax expense		-			-			-			-
NET LOSS	$	(93,446	)	$	(15,538	)	$	(219,333	)	$	(328,317	)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Six months ended June 30, 2022
REVENUE	$	33,467		$	5,480,579		$	-		$	5,514,046
COST OF REVENUE		(14,929	)		(4,878,813	)		-			(4,893,742	)
GROSS PROFIT		18,538			601,766			-			620,304
OTHER INCOME		4,285			94,945			-			99,230
OPERATING EXPENSES
General and administrative		(94,681	)		(618,348	)		(109,778	)		(822,807	)
(LOSS)/PROFIT FROM OPERATIONS		(71,858	)		78,363			(109,778	)		(103,273	)
FINANCE COSTS		(1,860	)		(3,785	)		-			(5,645	)
PROFIT/(LOSS) BEFORE TAX		(73,718	)		74,578			(109,778	)		(108,918	)
Tax expense		-			(12,678	)		-			(12,678	)
NET PROFIT/(LOSS)	$	(73,718	)	$	61,900		$	(109,778	)	$	(121,596	)

	As of June 30, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022
BGLC & Bionexus	$	323,500	$	677,477	$	81,439	$	108,390
Chemrex		7,575,440		8,062,685		1,853,735		1,966,759
TOTAL		7,898,940		8,740,162		1,935,174		2,075,149